Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease.
Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.
Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA.
For more information, please visit our website at www.apollotherapeutics.com
Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.
Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA.
For more information, please visit our website at www.apollotherapeutics.com
Employees: 11-50
Total raised: $405M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Reimagined... | reimagined... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.01.2024 | Series C | $33.5M | - |
| 08.09.2023 | Series C | $226.5M | - |
| 18.06.2021 | - | $145M | - |
Mentions in press and media 13
| Date | Title | Description |
| 02.01.2024 | Apollo Therapeutics Holds USD33.5M Second Close of Series C; Brings Round Total to $260M | Apollo Therapeutics, a Cambridge, UK and Boston, MA- and and Chicago, IL-based portfolio biopharmaceutical company focused on translating fundamental medical research into medicines, raised USD 33.5M in a second close of its Series C financ... |
| 02.01.2024 | UK’s Apollo Therapeutics completes second close of its Series C financing; raises additional €30.5M | Read this article in: Apollo Therapeutics, a biopharmaceutical company, has concluded its Series C financing with a second close, securing an additional $33.5M (approximately €30.52M) in December 2023. This brings the company’s total funds ... |
| 28.12.2023 | These are the 23 largest European funding rounds of 2023 | Read this article in: Over the last two decades, Europe’s startup ecosystem has transformed, evolving from an outsider to a global contender. The region hosts several prominent startup hubs, solidifying its position on the global tech stage... |
| 08.09.2023 | Apollo Therapeutics Raises $226.5M in Series C Financing | Apollo Therapeutics, a Cambridge, UK-, Boston, MA and Chicago, IL-based portfolio biopharmaceutical company, raised $226.5M in Series C funding. The round was led by Patient Square Capital, with participation from new investors including M&... |
| 06.09.2023 | Apollo Therapeutics closes $226.5 Million Series C financing led by Patient Square Capital | CAMBRIDGE, UK & BOSTON, US – Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, announces the close of $226.5 million in a Seri... |
| 17.11.2022 | Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development | |
| 18.06.2021 | Apollo Therapeutics Raises $145M in Funding | Apollo Therapeutics, a Cambridge UK-based biopharmaceutical company focused on advancing treatments based on breakthrough discoveries, raised $145M in funding. The round was led by Patient Square Capital, with participation from Rock Spring... |
| 18.06.2021 | ASTRAZENECA PLC University of Cambridge: Apollo Therapeutics launches with GBP100m investment; Pioneering collaboration initiated by the University of Cambridge, Imperial College London and Universit... | A pioneering collaboration to speed development of breakthrough medical discoveries-devised by the University of Cambridge, Imperial College London, University College London and embraced by pharmaceutical giants AstraZeneca, GlaxoSmithKlin... |
| 17.06.2021 | UCL, Imperial College London and University of Cambridge are behind innovative industry university collaboration receiving £100m funding to rapidly advance cutting-edge science | |
| 17.06.2021 | Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development | - |
Show more